gdc
FDA Approvals, News & UpdatesFollicular LymphomaNewsworthy

Aliqopa the Newest Treatment Approved for Relapsed Follicular Lymphoma

December 2017 Vol 3 No 6

On September 14, 2017, the FDA approved Aliqopa (copanlisib; from Bayer HealthCare) for the treatment of adults with relapsed follicular lymphoma who have received ≥2 previous systemic therapies.

“For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments. Options are limited for these patients and today’s approval provides an additional choice for treatment, filling an unmet need for them,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The approval of Aliqopa was based on a clinical trial showing improved response to therapy with this drug. Serious side effects with Aliqopa include infections, high blood sugar and blood pressure, inflammation of lung tissue, neutropenia, and severe skin reactions. Women who are breastfeeding should avoid this drug.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia
In September 2021, the FDA approved Brukinsa oral capsules for adults with relapsed or refractory marginal-zone lymphoma. And in August, the FDA approved Brukinsa for adults with Waldenström’s macroglobulinemia, a rare, slow-growing type of non-Hodgkin lymphoma.
FDA Approvals, News & UpdatesCervical Cancer
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
In September, the FDA approved Tivdak (tisotumab vedotin) for the treatment of women with recurrent or metastatic cervical cancer that progressed during or after chemotherapy. This is the first tissue factor–directed antibody and microtubule inhibitor conjugate approved for women with advanced cervical cancer.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest